Sight Sciences (NASDAQ:SGHT) CEO Sells 29,244 Shares

Key Points

• CEO Paul Badawi sold 29,244 shares on April 1 at an average price of $3.70 (≈$108,203), trimming his stake by 0.47% to 6,151,156 shares; he also sold 22,362 shares on Jan 16 at $6.62 and 11,870 shares on Jan 6 at $7.48.
• Sight Sciences shares traded around $3.52 (52‑week range $2.03–$9.24) with a $190.1M market cap; the company slightly beat quarterly EPS estimates (-$0.08 vs. -$0.15) but remains unprofitable, and analysts hold a consensus "Hold" rating with an average target of $8.31.

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CEO Paul Badawi sold 29,244 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $3.70, for a total value of $108,202.80. Following the transaction, the chief executive officer owned 6,151,156 shares of the company's stock, valued at $22,759,277.20. This represents a 0.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Paul Badawi also recently made the following trade(s):

• On Friday, January 16th, Paul Badawi sold 22,362 shares of Sight Sciences stock. The stock was sold at an average price of $6.62, for a total value of $148,036.44.
• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $88,787.60.

Sight Sciences Stock Performance

Sight Sciences stock remained flat at $3.52 during midday trading on Friday. 236,639 shares of the company's stock were exchanged, compared to its average volume of 413,049. Sight Sciences, Inc. has a 52-week low of $2.03 and a 52-week high of $9.24. The firm has a market cap of $190.10 million, a price-to-earnings ratio of -4.69 and a beta of 2.50. The stock has a fifty day moving average price of $4.87 and a two-hundred day moving average price of $5.73. The company has a current ratio of 10.22, a quick ratio of 9.52 and a debt-to-equity ratio of 0.63.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its earnings results on Wednesday, March 4th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.07. The firm had revenue of $20.39 million for the quarter, compared to analysts' expectations of $20.35 million. Sight Sciences had a negative return on equity of 55.72% and a negative net margin of 49.67%. Analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its stake in shares of Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company's stock worth $26,000 after acquiring an additional 3,785 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in shares of Sight Sciences during the fourth quarter worth $81,000. AXQ Capital LP acquired a new stake in shares of Sight Sciences during the fourth quarter worth $89,000. Tower Research Capital LLC TRC lifted its holdings in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock valued at $48,000 after purchasing an additional 2,875 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Sight Sciences during the fourth quarter valued at $96,000. Institutional investors own 55.51% of the company's stock.

Analyst Ratings Changes

SGHT has been the subject of several research analyst reports. UBS Group reduced their price objective on shares of Sight Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a report on Friday, March 6th. Cantor Fitzgerald set a $8.00 target price on shares of Sight Sciences in a research note on Monday, March 2nd. Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a research report on Monday, January 5th. William Blair reiterated an "outperform" rating on shares of Sight Sciences in a report on Thursday, March 5th. Finally, Citigroup lowered their price objective on shares of Sight Sciences from $9.10 to $6.50 and set a "neutral" rating on the stock in a research note on Friday, March 6th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $8.31.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.